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A B S T R A C T
Purpose
To deﬁne characteristics, treatment response, and outcomes of men with brain metastases (BM)
from germ cell tumors (GCT).
Patients and Methods
Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13
countries by using standardized questionnaires. Clinical features were correlated with overall
survival (OS) as the primary end point.
Results
BMwere present at initial diagnosis in 228men (groupA) and at relapse in 295men (groupB). OS at 3 years
(3-yearOS)wassuperior ingroupAversusgroupB (48%v27%;P, .001).MultipleBMand thepresenceof
liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal
nonseminoma (group A) and elevations of a-fetoprotein of 100 ng/mL or greater or of human chorionic
gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors.
Dependingon these factors, the3-yearOS ranged from0%to70% ingroupAand from6%to52%ingroup
B. In groupA, 99%of patients received chemotherapy;multimodality treatment or high-dose chemotherapy
was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of
patients received chemotherapy;multimodality treatmentwas associatedwith improved survival compared
with single-modality therapy (hazard ratio, 0.51; 95%CI, 0.36 to 0.73;P, .001), aswas high-dose compared
with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P 5 .001).
Conclusion
Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose che-
motherapy andmultimodality treatment seemed to improve survival probabilities inmenwithBMat relapse.
J Clin Oncol 34:345-351. © 2015 by American Society of Clinical Oncology
INTRODUCTION
In germ cell tumors (GCT), brain metastases
(BM), either synchronous at initial diagnosis
(group A) or metachronous at relapse (group
B), are a deﬁning feature of poor prognosis.1,2
Because BM of GCT are rare, their optimal
management remains controversial.3,4 Re-
ported retrospective series lack the power to
robustly identify tumor or patient character-
istics associated with outcome or to deﬁne
optimal treatment strategies; some groups
advocate chemotherapy alone,5,6 multimodality
treatment,7-12 or even radiotherapy and surgery
alone.13
Prospective trials are unlikely to be per-
formed, so we retrospectively collected data
on patients who had GCT with synchronous
or metachronous BM with or without addi-
tional tumor sites among members of the
Global Germ Cell Cancer Group. Here, we
compare tumor and patient characteristics,
treatments, and outcomes from this data
collection with the following goals: to identify
prognostic factors and to suggest manage-
ment strategies for each of these two clinical
scenarios.
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PATIENTS AND METHODS
Patients
Data on 582 patients with GCT and BM at initial diagnosis or at
relapse from 46 centers in 13 countries in the United States, Canada,
Australia, and Europe were retrospectively collected from standardized
detailed questionnaires and were reviewed by an international panel. Data
were manually entered into an ACCESS database and were checked for
plausibility and entry errors. In case of queries or data inconsistency, the
principal investigators at the participating centers were contacted.
Patient Eligibility
Inclusion criteria for the study were as follows: Male sex; age 15 years
or older; gonadal or extragonadal GCT either by histology or by
unequivocal tumor marker (a-fetoprotein or human chorionic gonado-
tropin [HCG]) elevation in conjunction with other ﬁndings consistent
with GCT diagnosis; BM present either at initial diagnosis or at relapse by
computed tomography or magnetic resonance scanning with or without
histologic conﬁrmation; diagnosis of BM between Jan 1, 1990, and Dec 31,
2013; minimal follow-up of 2 years after diagnosis of BM unless deceased;
and written consent by the principal investigator at participating centers to
allow site visits and support veriﬁcation of data entries, if requested.
Exclusion criteria included the following: BM diagnosis only post
mortem; previous treatment for BM or malignant brain tumors; and missing
data to an extent that did not allow inclusion in a prognostic factor analysis (eg,
such as missing data on treatment outcome and survival). If repetitive and
relevant queries on data quality occurred at a participating center, or if a
participating center refused site visits for veriﬁcation of data entry, all patients
from this center were excluded from analysis. The study protocol was approved
centrally by the ethics committee from the University of Marburg, Germany.
Each center was required to obtain additional institutional approval.
Data from 59 patients were excluded from the current analysis for the
following reasons: primary germ cell cancer of the brain (n5 27), follow-up for
fewer than 2 years (n 5 15), incomplete data (n 5 10), no germ cell cancer
histology (n 5 2), treatment before 1990 (n 5 2), female sex (n 5 1), age
younger than 15 years (n5 1), and death on the day of diagnosis of BM(n5 1).
Statistics
All statistical analyses were performed by a biostatistician (A.K.) from
the coordinating center using STATA, version 11 (StataCorp LP, College
Station, TX). Univariable descriptive statistics were performed with fre-
quencies and percentages used for categoric variables and medians and
ranges used for continuous variables.
The primary end point for the prognostic factor analysis was overall
survival (OS), and progression-free survival (PFS) was a secondary end point.
The Kaplan-Meier method was used to estimate survival rates, presented at 3
years. When applicable, median survival times as well as survival curves and
smoothed estimates of the hazard rates also are provided.
For patients who received ﬁrst-line treatment (group A), all survival-
related end points were calculated from initiation of ﬁrst-line treatment,
whatever modality was chosen. For patients who had experienced relapse
(group B), all survival-related end points were calculated from the ini-
tiation of the ﬁrst day of salvage treatment, whatever modality was chosen.
PFS was calculated from the start of treatment and ended at the time of
ﬁrst disease progression or death as a result of progression. Patients with death
as a result of causes other than progression were censored at the time of death.
OS was calculated from the start of treatment and ended at the date of death.
Patients alive at last follow-up were censored at the last known date alive.
Univariable analyses were performed with the log-rank test. Multi-
variable analyses were performed with the Cox proportional hazards
regression model. Results that compared groups were presented with
hazard ratios (HRs) and the associated 95% CIs. The proportional hazards
assumptions were tested via Schoenfeld residuals.
Variables other than treatment with univariable signiﬁcance of P# .10
were entered in the multivariable analysis. The results of the multivariable
analysis were used to deﬁne a prognostic score that was based on a com-
bination of variables with independent prognostic signiﬁcance. Associations
between treatment type and outcome were evaluated with the Cox model,
adjusted for prognosis and compared within prognostic groups.
RESULTS
Of 582 patients, 523 (90%) fulﬁlled the entry criteria of the study and
were considered eligible for the analysis. Details on characteristics,
treatments, and outcomes in patients with synchronous BM at initial
diagnosis (groupA; n5 228) andmetachronous BMat relapse (group
B; n5 295 patients) are presented in Table 1. The median time from
the previous response to the occurrence of metachronous BM in
patients who experienced disease relapse from group B was 3 months
(range, 0 to 74 months).
BM occurred almost exclusively in patients with non-
seminoma histology. Although the locations of primary tumors
between the two groups were similar, other relevant patient charac-
teristics at initial diagnosis and at relapse were distinct. Among patients
in group A, a signiﬁcantly higher proportion had high HCG levels at
presentation compared with patients from group B. More than half of
patients (53%) in group A had initial values of HCG greater than
100,000 U/L. Only 17% of patients with BM at initial diagnosis had
normal or moderate elevations of HCG of 1,000 U/L or less.
Signiﬁcantly more patients in group A than in group B had
multiple BM (67% v 56%; P,.05) and concurrent systemic disease
(99% v 72%; P, .05). In particular, liver and/or bone involvement
was signiﬁcantly more common among patients in group A than in
group B (46% v 25%; P , .001).
Almost all patients in group A had concurrent pulmonary
metastases (94%) at initial presentation, and 47% of patients were
asymptomatic with respect to their BM. This contrasts with a 62%
rate of concurrent pulmonary metastases and a 30% rate of
asymptomatic patients in group B (P , .05 for both).
Survival
PFS rates at 2 yearswere signiﬁcantly higher in groupA (29%; 95%
CI, 23% to 35%) than in group B (21%; 95%CI, 16% to 26%; P, .05;
Fig 1A). Relapses beyond 2 years were uncommon in either group
(Appendix Fig A1A, online only). Progression in the brain after
treatment occurred in 86 (54%) of 158 patients who had documented
progression in group A and in 113 (49%) of 230 patients in group B
(Appendix Table A1, online only). In group A, the 3-year OS was 48%
(95%CI, 42% to 55%), and themedian OSwas 29.5 months. In group
B, the 3-year OS was 27% (95% CI, 22% to 32%), and the median OS
was only 8months (P, .001; Fig 1B). Not all patients died as a result of
uncontrolled BM. Only 66 (52%) of 128 patients in group A and 102
(45%) of 225 patients in group B died as a result of GCT with
documented progression of BM. Deaths beyond 3 years were
uncommon in either group (Appendix Fig A1B).
Multivariable Analysis and Prognosis in Group A
In group A, three variables were signiﬁcantly associated with poor
OS in the multivariable analysis. These were mediastinal primary site
for patients with nonseminoma (HR, 1.66; 95% CI, 0.98 to 2.82), the
presence of liver and/or bone metastases (HR, 2.11; 95% CI, 1.47 to
3.03), and the presence of multiple BM (HR, 1.88; 95% CI, 1.24 to
2.85; Table 2). Although OS decreased with increasing number of BM
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in univariable analysis, use of a higher cutoff or multiple categories did
not increase the discriminatory power of the multivariable model.
Because the regression model coefﬁcients were similar, one point was
assigned for each of these three variables, and a score that ranged from
0 to 3was obtained by summing the number of points for each patient.
Thus, a total of four prognostic groups were identiﬁed: low
risk (score, 0; 16% of patients; 3-year OS, 71%), intermediate risk
(score, 1; 51% of patients; 3-year OS, 54%), high risk (score, 2;
29% of patients; 3-year OS, 30%), and very high risk (score, 3; 4%
of patients; 3-year OS, 0%; Table 2; Fig 2A).
Multivariable Analysis and Prognosis in Group B
Three variables were signiﬁcantly associated with poor OS in
multivariable analysis in patients from group B (Table 3): multiple
BM (HR, 2.00; 95%CI, 1.40 to 2.87), liver and/or bonemetastases (HR,
1.92; 95% CI, 1.29 to 2.84), and at least one elevated tumor marker,
deﬁned as an a-fetoprotein of 100 ng/mL or greater or an HCG of
5,000 U/L or greater (HR, 2.11; 95% CI, 1.48 to 3.02). Similar to
group A, an increasing number of BM did not change the
multivariable prognostic score, despite inferior survival.
Although one third of patients in group B had missing marker
values (n 5 103; 35%), this important variable was retained in
the model, because patient characteristics and prognostic scores
were similarly distributed among patients with and without
missing data (3-year OS for patients with missing data v full
data: 28% v 26%; HR, 0.92; 95% CI, 0.70 to 1.22; P 5 .57). In
group B, patients with isolated BM at relapse were more often
treated with either surgery or radiotherapy alone but had similar
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
Group A: Brain
Metastases at Diagnosis
(n = 228)
Group B: Brain
Metastases at Relapse
(n = 295)
Total
(N = 523)
No. % No. % No. %
Age, years
, 30 125 54.8 142 48.1 267 51
$ 30 103 45.2 153 51.9 256 49
Primary tumor site
Testis 197 86.4 245 83.1 442 84.5
Retroperitoneum 8 3.5 14 4.7 22 4.2
Mediastinum 17 7.5 32 10.8 49 9.4
Other 6 2.6 4 1.4 10 1.9
Histology
Seminoma 9 4.0 14 4.7 23 4.4
Nonseminoma 216 95.0 280 94.9 496 94.8
Unknown 3 1.0 1 0.4 4 0.8
AFP, ng/mL
# 10 100 43.9 128 43.4 228 43.6
. 10 to # 1,000 61 26.7 49 16.6 110 21.0
. 1,000 to # 10,000 19 8.3 16 5.4 35 6.7
. 10,000 13 5.7 6 2.0 19 3.6
Unknown 35 15.4 96 32.6 131 25.1
HCG, IU/L
# 10 11 4.8 74 25.1 85 16.3
. 10 to # 100 8 3.5 29 9.9 37 7.1
. 100 to # 1,000 18 7.9 33 11.1 51 9.8
. 1,000 to # 50,000 41 18.0 49 16.6 90 17.2
. 50,000 to # 100,000 24 10.5 6 2.0 30 5.7
. 100,000 114 50.0 9 3.1 123 23.5
Unknown 12 5.3 95 32.2 107 20.4
Brain metastases
Single 69 30.3 119 40.3 188 36.0
Multiple 141 61.8 149 50.5 290 55.4
Number unknown 18 7.9 27 9.2 45 8.6
Brain only 2 0.9 82 27.8 84 16.1
Brain and outside brain 226 99.1 213 72.2 439 83.9
Metastatic site
Lung 215 94.3 184 62.4 399 76.3
Mediastinum 1 0.4 43 14.6 44 8.4
Abdomen 135 59.2 93 31.5 228 43.6
Bone 14 6.1 32 10.8 46 8.8
Liver 96 42.1 57 19.3 153 29.3
Liver and/or bone 104 45.6 75 25.4 179 34.2
Clinical symptoms
Any symptom 121 53.0 208 70.5 329 62.9
Seizures 31 13.6 59 20.0 90 17.2
Headache 58 25.4 93 31.5 151 28.9
Abbreviations: AFP, a-fetoprotein; HCG, human chorionic gonadotropin.
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outcomes to patients who experienced relapse with BM and
systemic metastases (data not shown).
Similar to group A, a prognostic score was calculated for each
patient in group B by assigning each adverse factor a score of 1,
which resulted in a score sum that varied from 0 to 3. Because the
outcomes for patients with score values of 2 or 3 were equally poor
(6% and 5% 3-year OS, respectively), these two groups were
combined to result in three prognostic groups: low risk (score, 0;
22% of patients; 3-year OS, 52%), intermediate risk (score, 1; 41%
of patients; 3-year OS, 30%) and high risk (score, 2 or 3; 37% of
patients; 3-year OS, 7%; Table 3; Fig 2B).
Treatments and Outcomes in Group A
Single-modality treatment was used in 103 patients (45%), and
multimodality treatmentwas used in 125 patients (55%). Chemotherapy
was administered in almost all patients across the four prognostic
groups (99%). In contrast, neurosurgical resection varied by prognostic
group and was more frequently used in patients with low risk (41%)
versus intermediate risk (21%), high risk (7%), or very high risk (0%;
P , .001; Appendix Tables A2 and A3, online only). Neurosurgical
resections were not associated with improved OS in the multivariable
analysis (adjusted HR, 0.81; 95% CI, 0.46 to 1.39; P 5 .44).
An uneven distribution across the prognostic groups was also
observed for the use of radiation therapy in patients with low risk
(44%), intermediate risk (52%), high risk (36%), and very high
risk (22%; P,.10; Appendix Table A3).Whole-brain irradiation in
92 (92%) of 100 patients was not associated with a signiﬁcant
improvement in OS in multivariable analysis (adjusted HR, 0.77;
95% CI, 0.53 to 1.12; P 5 .17).
As a result, in group A, improved outcome with multimodality
treatment versus single-modality treatment was signiﬁcant in the
univariable analysis (HR, 0.57; 95% CI, 0.40 to 0.80; P , .001), but
this beneﬁt lost signiﬁcance after adjustment for prognostic group
classiﬁcation in the multivariable analysis (HR, 0.71; 95% CI, 0.49 to
1.03; P5.07; Appendix Fig A2, online only). There was also no beneﬁt
of improvedOS associated with the use of high-dose chemotherapy in
univariable analysis (HR, 0.86; 95% CI of HR, 0.46 to 1.59; P5 .62),
although this treatment was used infrequently in patients from group
A, which limited the potential of this analysis (Appendix Table A2).
Treatments and Outcomes in Group B
Compared with group A, fewer patients in group B received
chemotherapy either alone or in combination with other therapies
(99% v 58%; P , .05). Instead, signiﬁcantly more patients in group B
underwent surgery alone, radiation therapy alone, or surgery in
combination with radiation therapy (Appendix Table A4, online only).
This applied particularly to patients with isolated metachronous BM at
relapse without other systemic metastatic sites. Chemotherapy was
more frequently given as high-dose chemotherapy in group B than in
group A (56 [19%] of 295 patients in group B v 22 [10%] of 228
patients in groupA; P,.05).Whole-brain irradiationwas administered
in 177 (89%) of 199 patients. Overall, a greater variability of treatments
was observed in group B than in group A (Appendix Table A4).
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Fig 1. (A) Progression-free survival in patients with brain metastases at initial diagnosis (group A) and at relapse (group B). (B) Overall survival in patients with brain
metastases at initial diagnosis (group A) and at relapse (group B).
Table 2. OS According to Signiﬁcant Variables in Patients With Synchronous
Metastases at Initial Diagnosis (group A)
Prognostic Variable
Multivariable Analysis
ScoreHR (95% CI) P
Primary site .059
Testis/retroperitoneum 1 0
Mediastinum/other 1.66 (0.98 to 2.82) 11
Liver and/or bone , .001
No liver/bone 1 0
Liver or bone 2.11 (1.47 to 3.03) 11
No. of brain metastases .003
Single 1 0
Multiple 1.88 (1.24 to 2.85) 11
Prognostic score* 3-Year OS Probability
Low risk (n = 32) 1 .707 0
Intermediate risk (n = 108) 1.70 (0.89 to 3.25) .543 1
High risk (n = 61) 3.31 (1.71 to 6.40) .295 2
Very high risk (n = 9) 6.98 (2.87 to 16.96) 0 3
Abbreviations: HR, hazard ratio; OS, overall survival.
*Eighteen patients were not classiﬁed because of missing data.
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Radiation therapy and chemotherapy were used with similar
frequency throughout the prognostic groups. Similar to group A,
surgery was more frequently used in patients in group B with low
risk (53%) than with intermediate (35%) and high (16%) risks
(Appendix Table A5, online only).
Chemotherapy (HR, 0.64; 95% CI, 0.49 to 0.83; P , .001),
surgery (HR, 0.55; 95% CI, 0.41 to 0.72; P 5 .001), radiation
therapy (HR, 0.70; 95% CI, 0.53 to 0.92; P 5 .01), and high-dose
chemotherapy (HR, 0.51; 95% CI, 0.34 to 0.77; P 5 .001) were all
associated with signiﬁcantly improved OS in univariable analysis.
In multivariable analysis stratiﬁed by prognostic groups, only the
use of multimodality treatment (HR, 0.52; 95% CI, 0.37 to 0.73;
P, .001) and high-dose chemotherapy (HR, 0.41; 95% CI, 0.24 to
0.69; P , .001) remained signiﬁcant (Fig 3).
DISCUSSION
Little is known about the presentation, prognostic factors, treatment,
or outcome of patients with BM fromGCT.3,4We demonstrated that
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Fig 2. (A) Overall survival (OS) according to prognosis in patientswith synchronousmetastases at initial diagnosis (group A). (B) OS according to prognosis in patientswith
metachronous metastases at relapse (group B).
Table 3. OS According to Signiﬁcant Variables in Patients With Metachronous
Metastases at Relapse (group B)
Prognostic Variable
Multivariable Analysis
ScoreHR (95% CI) P
No. of brain metastases , .001
Single 1 0
Multiple 2.00 (1.40 to 2.87) 11
Liver and/or bone , .001
No liver/bone 1 0
Liver or bone 1.92 (1.29 to 2.84) 11
AFP and HCG , .001
Both low* 1 0
At least one high 2.11 (1.48 to 3.02) 11
Prognostic score† 3-Year OS Probability
Low risk (n = 43) 1 .516 0
Intermediate risk (n = 79) 1.97 (1.20 to 3.25) .297 1
High risk (n = 70) 4.46 (2.70 to 7.37) .071 2-3
NOTE. A total of 103 patients were not classiﬁed because of missing data.
Abbreviations: AFP, a-fetoprotein; HCG, human chorionic gonadotropin; HR,
hazard ratio; OS, overall survival.
*AFP # 100 ng/mL and HCG # 5,000 IU/L.
†The 3-year OS prognostic score for patients with missing data versus full data
was 0.278 versus 0.261 (HR, 0.924; 95% CI, 0.701 to 1.217; P = .57).
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Fig 3. Results of multivariable analysis of treatments in patients with meta-
chronous brain metastases at relapse (group B): (A) multimodality versus single-
modality treatment and (B) high-dose versus conventional-dose chemotherapy.
HR, hazard ratio.
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greater than 50% of patients with either synchronous BM at the time
of initial diagnosis or metachronous BM at relapse experience disease
progression and die within 1 year after the diagnosis of BM and that
approximately half of those patients died as a result of systemic
progression rather than uncontrolled BM. Patients who present with
adverse prognostic factors in addition to BM, and particularly those
who experience relapse withmetachronous BM, haveworse outcomes.
The absence of symptoms did not exclude even widespread
metastatic brain disease in either group; almost half of the patients
who presented with BM and one third of patients who experienced
relapse with BM were asymptomatic. BM was associated with non-
seminoma histology, with a high frequency of pulmonary or liver and/
or bonemetastases, and with high serum levels of HCG. BM therefore
may be more frequent in patients with a high systemic burden of
disease, particularly those with lung metastases and high HCG levels
or those who experience relapse after cisplatin-based chemotherapy,
whereas the likelihood of BM in the absence of these features is low.
Our results demonstrated signiﬁcant differences between
patients who present with synchronous BM at initial diagnosis
versus those who experience relapse. Patients with synchronous BM
at initial diagnosis tend to have a higher burden of systemic disease
than those who experience relapse in the brain. Yet, despite this
higher burden of disease, these patients still have better prognoses
than previously treated patients, which suggests that chemotherapy
resistance is a critically important driver of outcome.
In contrast, multivariable analysis showed that the number of BM
and the presence of liver and/or bone metastases were signiﬁcantly
associatedwith a poor outcome in both groups of patients, which points
toward similarities in the factors that determine outcome in these
otherwise-distinct groups of patients. The large number of patients in
the present analysis allowed us to develop well-deﬁned and discrim-
inatory prognostic models for patients who presented with synchro-
nous BM at initial diagnosis as well as in those who had metachronous
BMat relapse; thesemodels provide accurate estimates of the likelihood
of cure and survival in these rare but important clinical scenarios.
Treatment guidelines for untreated metastatic GCT are
straightforward and focus heavily on cisplatin-based combination
treatment.3 Existing guidelines are much less clear for patients with
GCT and BM, for which management usually is based on indi-
vidual or institutional preferences. This may in part explain the
large heterogeneity of treatments found in the present analysis. The
retrospective nature, selection bias, disproportional representation
of treatment frequencies, and other potentially confounding fac-
tors limit the assessment of treatment strategies applied in patients
from this data collection. Nevertheless, because we identiﬁed well-
deﬁned prognostic subgroups, a few important observations about
treatment strategies can be made.
First, almost all patients who presented with synchronous
BM at initial diagnosis received chemotherapy. Patients with
better prognostic features were more likely to be offered
additional radiotherapy or neurosurgical resections. However,
despite trends in favor of multimodality treatment, multi-
variable analysis in the present data set did not support the
general use of neurosurgery and/or radiation therapy in addi-
tion to chemotherapy, particularly not for patients with low
risk. On the basis of these results, we suggest that chemotherapy
should remain the standard of care in patients who present with
synchronous BM at initial diagnosis to avoid additional toxicity
from multimodality treatment, whereas additional radiation therapy
and/or neurosurgery may be used in particular clinical circumstances
according to individual decisions. The number of patients treated with
stereotactic radiation was too small to assess the impact of this
modality. Similarly, althoughwe did not ﬁnd a beneﬁt from high-dose
chemotherapy versus conventional-dose chemotherapy in multi-
variable analysis of patients with synchronous BM at initial diagnosis,
the numbers of patients treated with this intensive systemic approach
as ﬁrst-line therapy were too small to draw deﬁnite conclusions.
Second, the greater variability in the management of patients
who experienced relapse with metachronous BMmay in part reﬂect
the lack of evidence for their optimal treatment.3,4 Our analysis
provided a broad overview of current management practices. In
univariable analysis, all treatments evaluated in patients with
metachronous BM resulted in improved OS. However, only the use
high-dose chemotherapy and multimodality treatment were asso-
ciated with a superior outcome in the multivariable analysis, par-
ticularly in patients with intermediate and poor risks. This contrasts
with patients who had synchronous BM at initial diagnosis, in whom
high-dose chemotherapy and multimodality treatment were not
signiﬁcantly associated with improved OS. Therefore, on the basis of
the current analysis, the application of the latter two strategies may
be important to maximize the outcome only for patients with GCT
who experience relapse with metachronous BM.
The current analysis is associated with all the shortcomings of
a retrospective series, which include selection bias, reporting bias,
missing data, a diversity of treatment approaches and regimens, as
well as other potential confounders of outcome. Nevertheless, this
large series describes prognostic factors and supports decision
making in a clinical scenario that previously lacked robust data.
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GLOSSARY TERMS
Cox proportional hazards regression model: a statistical
model for regression analysis of censored survival data, examining the
relationship of censored survival distribution to one or more covariates.
This model produces a baseline survival curve, covariate coefﬁcient esti-
mateswith their standard errors, risk ratios, 95%CIs, and signiﬁcance levels.
prognostic factor: a measurable patient characteristic that is
associated with the subsequent course of disease (whether or not
therapy is administered). The identiﬁcation of a prognostic factor does
not necessarily suggest a cause-and-effect relationship. However, within
a suitable outcome model, the measurement of a prognostic factor
contributes to an estimate of an outcome probability (eg, the probability
of disease-free survival within a given time interval).
prognostic model: a combination of patient, tumor, and treatment
characteristics that predict the outcome of individual patients.
progression-free survival: time from random assignment until
death or ﬁrst documented relapse, categorized as either locoregional
(primary site or regional nodes) failure or distant metastasis or death.
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Integrata di Verona, Verona, Italy (n5 15); Eric WilliamWinquist, Lawson Health Research Institute, London, Ontario, Canada (n
5 14); Ugo De Giorgi, (Istituto Scientiﬁco Romagnolo per lo Studio e la Cura dei Tumori) Istituto di Ricovero e Cura a Carattere
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Zaragoza, Spain (n 5 4); Xavier Garcia del Muro, Institut Catala` d’Oncologia L’Hospitalet, Barcelona, Spain (n 5 4); Jeff White,
BeatsonWest of Scotland Cancer Centre, Glasgow, United Kingdom (n5 4); Richard Cathomas, Kantonsspital Graubu¨nden, Chur,
Switzerland (n5 3); Sergio Va´zquez, Hospital Universitario Lucus Augusti, Lugo, Spain (n5 3); Javier Sastre, Hospital Clinico San
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General Universitario Gregorio Maranon; Madrid, Spain (n 5 2); Marta Lopez-Brea, Hospital Marques De Valdecilla, Santander,
Spain (n 5 2); Regina Girones, Hospital Lluis Alcanyis, Valencia, Spain (n 5 2); Michele Aieta, Istituto di Ricovero e Cura a
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Table A1. Patients With Progression of Brain Metastases, Among All Patients Who Experienced Progression, According to Treatment Modality
Treatment
No. (%) of Patients
Group A Group B
No Progression With BM Progression With BM No Progression With BM Progression With BM
CT alone 34 (44) 43 (56) 11 (46) 13 (54)
CT 1 RT 25 (46) 29 (54) 34 (53) 30 (47)
CT 1 surgery 8 (47) 9 (53) 6 (33) 12 (67)
CT 1 RT 1 surgery 5 (56) 4 (44) 7 (50) 7 (50)
RT alone — 1 (100) 43 (68) 20 (32)
Surgery alone — — 6 (33) 12 (67)
Surgery 1 RT — — 10 (34) 19 (66)
Total 72 (46) 86 (54) 117 (51) 113 (49)
Abbreviations: BM, brain metastases; CT, chemotherapy; RT, radiotherapy.
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Table A3. Distribution of Treatments Within Prognostic Groups in Patients With Brain Metastases at Initial Diagnosis (group A)
Variable
No. (%) of Patients by Prognostic Group
Low (n = 32) Intermediate (n = 107) High (n = 61) Very High (n = 9)
Combination
Only chemotherapy 6 41 36 7
CT then surgery 4 4 2 —
CT then RT 6 29 11 1
CT then surgery then RT — 1 — —
Surgery then CT 8 6 1 —
Surgery then RT then CT — 6 — —
Surgery then RTCT 1 4 1 —
Only RT — — — —
RT then CT 4 5 3 —
RTCT 3 10 7 1
RTCT then surgery — 1 — —
Surgery (P , .001)
No 19 (59) 85 (79) 57 (93) 9 (100)
Yes 13 (41) 22 (21) 4 (7) —
RT (P = .10)
No 18 (56) 51 (48) 39 (64) 7 (78)
Yes 14 (44) 56 (52) 22 (36) 2 (22)
CT (P = .12)
Conventional 32 (100) 93 (87) 54 (89) 9 (100)
High dose — 14 (13) 7 (11) —
Combined modality treatment (P , .001)
Only chemotherapy 6 (19) 41 (38) 36 (59) 7 (78)
Combined modality 26 (81) 66 (62) 25 (41) 2 (22)
NOTE. Nineteen patients were not classiﬁed.
Abbreviations: CT, chemotherapy; RT, radiation therapy; RTCT, radiation therapy and chemotherapy.
Table A2. Univariable Analysis of OS According to Treatment in Patients With Synchronous Metastases at Initial Diagnosis in Group A
Treatment
No. of Patients
(n = 228)
No. of Events
(n = 128)
3-Year OS
Probability HR (95% CI) P
Combination* .012
Only CT 102 68 0.342
CT then surgery 11 5 0.614
CT then RT 49 24 0.549
CT then surgery then RT 1 1 0
Surgery then CT 15 6 0.733
Surgery then RT then CT 6 2 0.667
Surgery then RTCT 6 2 0.667
Only RT 1 1 0
RT then CT 12 8 0.486
RTCT 24 11 0.486
RTCT then surgery 1 0 —
Surgery†
No 188 112 0.444
Yes 40 16 0.670 0.581 (0.34 to 0.98) .04
RT†
No 128 79 0.412
Yes 100 49 0.577 0.697 (0.49 to 1.00) .05
CT†
Conventional 204 116 0.484
High dose 22 11 0.475 0.857 (0.46 to 1.59) .62
Treatment modality
Single 103 69 0.339
Multiple 125 59 0.604 0.559 (0.39 to 0.79) , .001
Abbreviations: CT, chemotherapy; HR, hazard ratio; OS, overall survival; RT, radiation therapy; RTCT, radiation therapy and chemotherapy.
*Detailed information was missing in two patients.
†Detailed information was missing in one patient.
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Table A4. Univariable Analysis of OS According to Treatments in Patients With Metachronous Metastases in Group B
Treatment
No. of Patients
(n = 295)
No. of Events
(n = 225)
3-Year OS
Probability HR (95% CI) P
No treatment or palliative care 22 22 0.091
Combination
Only chemotherapy 30 22 0.188
CT then surgery 6 4 0.333
CT then RT 23 17 0.228
CT then surgery then RT 4 2 0.500
Only surgery 18 16 0.167
Surgery then CT 20 12 0.450
Surgery then RT 34 22 0.401
Surgery then RT then CT 14 8 0.643
Surgery then RTCT 6 3 0.500
Only RT 49 44 0.125
RT then CT 34 27 0.235
RTCT 31 21 0.323
RTCT then surgery 1 1 0.000
Surgery
No 189 155 0.196
Yes 106 70 0.399 0.545 (0.41 to 0.73) , .001
RT
No 96 78 0.226
Yes 199 147 0.290 0.696 (0.53 to 0.92) .001
CT
No 123 104 0.201
Yes 172 121 0.316 0.640 (0.49 to 0.83) , .001
CT type
Conventional 108 84 0.235
High dose 56 32 0.464 0.512 (0.34 to 0.77) .001
Treatment modality
Single 119 106 0.141
Multimodality 176 119 0.355 0.43 (0.33 to 0.57) , .001
Abbreviations: CT, chemotherapy; HR, hazard ratio; OS, overall survival; RT, radiation therapy; RTCT, radiation therapy and chemotherapy.
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Fig A1. (A) Hazard rate for progression in patients with brain metastases at initial diagnosis (group A) and at relapse (group B). (B) Hazard rate for death in patients with
brain metastases at initial diagnosis (group A) and at relapse (group B).
Table A5. Distribution of Treatments Within Prognostic Groups in Patients With Brain Metastases at Relapse (group B)
Treatment
No. (%) of Patients by Prognostic Group
Low (n = 43) Intermediate (n = 79) High (n = 70) Missing (n = 103)
No treatment of brain metastases — 4 9 9
Combination
Only chemotherapy 7 10 7 6
CT then surgery 2 3 1 —
CT then RT 3 12 3 5
CT then surgery then RT 2 1 1 —
Only surgery 1 4 1 12
Surgery then CT 3 6 1 10
Surgery then RT 10 4 4 16
Surgery then RT then CT 4 6 1 3
Surgery then RTCT 1 3 — 2
Only RT 2 11 20 16
RT then CT 4 7 9 14
RT then CT then surgery — 1 1 1
RTCT 4 7 11 9
RTCT then surgery — — 1 —
Surgery
No 20 (47) 51 (65) 59 (84) 59 (57)
Yes 23 (53) 28 (35) 11 (16) 44 (43)
RT
No 13 (30) 27 (34) 19 (27) 37 (36)
Yes 30 (70) 52 (66) 51 (73) 66 (64)
CT
No 13 (30) 23 (29) 34 (49) 53 (51)
Yes 30 (70) 56 (71) 36 (51) 50 (49)
CT type
Conventional 22 (76) 35 (65) 25 (76) 26 (54)
High dose 7 (24) 19 (35) 8 (24) 22 (46)
Multimodality treatment
Single modality 10 (23) 29 (37) 37 (53) 43 (42)
Multimodality 33 (76) 50 (63) 33 (47) 60 (58)
NOTE. A total of 103 patients were not classiﬁed.
Abbreviations: CT, chemotherapy; RT, radiation therapy; RTCT, radiation therapy and chemotherapy.
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Fig A2. Multivariable results of multimodality treatment in patients with synchronous brain metastases at initial diagnosis (group A). HR, hazard ratio.
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